---
title: "Changes from original"
bibliography: references.bib
vignette: >
  %\VignetteIndexEntry{Changes from original}
  %\VignetteEngine{quarto::html}
  %\VignetteEncoding{UTF-8}
---

In this vignette, you'll find a description of the changes that have
been made to the OSDC algorithm since its
[original validation](https://doi.org/10.2147/CLEP.S407019). The osdc
package uses the latest changes to the algorithm. Potential changes to
the algorithm, rather than the specific implementation and code details,
that we might in the future will also be described in this vignette. We
will also provide validation metrics here whenever we make a change, and
track these validations over the different versions.

## Specific changes since the original validation (version from the paper)

### Version 1.0

1. Purchases of GLP1-RA, dapagliflozin or empagliflozin are no longer
   used for inclusion nor type-classification.
   - Due to increasing use in treatment of non-diabetes.
2. For T1D classification, the window of 180 days to make a purchase of
   an insulin is now evaluated from the date of the first purchase of a
   glucose-lowering drug, rather than the date of inclusion.
   - To simplify computations and increase robustness to noise and
     atypical cases.
3. Purchases of insulin in the previous year is no longer required for
   T1D classification.
   - Because we found that the vast majority of individuals classified
     as T2D due to this criteria, reported that they had T1D in the data
     from Health in Central Denmark.
4. The logic defining pregnancy index dates has been simplified to only
   use diagnoses of pregnancy endings (no longer uses data on maternal
   care visits).
   - For the sake of simplicity, as we found no impact on classification
     accuracy in the Health in Central Denmark data.
5. HbA1c samples taken on the same date are de-duplicated.
   - To better align with recommended diagnostic practice [@WHO2011]. In
     the original implementation, only samples taken at the exact same
     time were de-duplicated.

## Validity

The validity of the OSDC algorithm is tested against self-reported
diabetes type in the Health in Central Denmark survey. The results are
reported as overall PPV (positive predictive value) and sensitivity for
each version of the algorithm and within subsets of the diabetes
population reporting onset of diabetes before or after age 40,
respectively, similar to tables 1 & 2 of the original validation paper
[@Isaksen2023].

### Validity in 2019

This uses the same data as
[the original validation paper](https://doi.org/10.2147/CLEP.S407019)
and provides a direct comparison to the original implementation.

#### Stratified by diabetes type and age at onset

| Version | Diabetes type | PPV   | Sensitivity |
|---------|---------------|-------|-------------|
| Paper   | T1D           | 0.943 | 0.773       |
| Paper   | T1D \>40 yrs  | 0.708 | 0.378       |
| Paper   | T2D           | 0.875 | 0.944       |
| Paper   | T2D \<40 yrs  | 0.471 | 0.863       |

| Version | Diabetes type | PPV   | Sensitivity |
|---------|---------------|-------|-------------|
| 1.0     | T1D           | 0.944 | 0.783       |
| 1.0     | T1D \>40 yrs  | 0.708 | 0.378       |
| 1.0     | T2D           | 0.879 | 0.944       |
| 1.0     | T2D \<40 yrs  | 0.480 | 0.863       |

#### Bootstrapped metrics

Corresponds to supplementary table S3 of the validation paper.

| Version | Diabetes type | Sensitivity | Specificity | PPV   | NPV   |
|---------|---------------|-------------|-------------|-------|-------|
| Paper   | T1D           | 0.774       | 0.999       | 0.951 | 0.997 |
| Paper   | T2D           | 0.943       | 0.989       | 0.878 | 0.995 |

| Version | Diabetes type | Sensitivity | Specificity | PPV   | NPV   |
|---------|---------------|-------------|-------------|-------|-------|
| 1.0     | T1D           | 0.788       | 0.999       | 0.947 | 0.997 |
| 1.0     | T2D           | 0.940       | 0.990       | 0.881 | 0.995 |

### Validity in 2025

This section will contain metrics from validation performed in
subsequent survey waves of Health in Central Denmark, as this data
becomes available.

## Potential future changes

1. Add support for using medical birth register to define pregnancies to
   censor gestational diabetes (GDM). This will allow for the censoring
   of glucose-lowering drug (GLD) purchases all the way back to 1995
   (rather than 1997 onward, as the obstetric codes are limited to), and
   enable the extension of the window of valid dates of diagnosis to
   1996 onward.
2. Limit the historic scope of primary diagnoses used to evaluate
   majority of diabetes-specific diagnoses in type classification (e.g.
   only evaluate majority among the last five type-specific diabetes
   diagnoses).

## References